MA50914A - Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes - Google Patents

Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes

Info

Publication number
MA50914A
MA50914A MA050914A MA50914A MA50914A MA 50914 A MA50914 A MA 50914A MA 050914 A MA050914 A MA 050914A MA 50914 A MA50914 A MA 50914A MA 50914 A MA50914 A MA 50914A
Authority
MA
Morocco
Prior art keywords
drh12
coding sequences
viral vectors
treatment methods
vectors including
Prior art date
Application number
MA050914A
Other languages
English (en)
Inventor
Robin R Ali
Alexander J Smith
Debra A Thompson
Original Assignee
Univ Michigan Regents
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents, Ucl Business Ltd filed Critical Univ Michigan Regents
Publication of MA50914A publication Critical patent/MA50914A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01105—Retinol dehydrogenase (1.1.1.105)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA050914A 2017-11-15 2018-11-15 Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes MA50914A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762586624P 2017-11-15 2017-11-15

Publications (1)

Publication Number Publication Date
MA50914A true MA50914A (fr) 2020-09-23

Family

ID=66431192

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050914A MA50914A (fr) 2017-11-15 2018-11-15 Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes

Country Status (15)

Country Link
US (2) US20190142909A1 (fr)
EP (2) EP3710590A4 (fr)
JP (2) JP2021502978A (fr)
KR (1) KR20200088385A (fr)
CN (2) CN117752822A (fr)
AU (1) AU2018367606A1 (fr)
BR (1) BR112020009828A2 (fr)
CA (1) CA3082586A1 (fr)
EA (1) EA202091194A1 (fr)
IL (2) IL274609B2 (fr)
MA (1) MA50914A (fr)
MX (1) MX2020005008A (fr)
PH (1) PH12020551319A1 (fr)
SG (1) SG11202004527YA (fr)
WO (1) WO2019099696A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022232249A1 (fr) * 2021-04-27 2022-11-03 The Trustees Of Columbia University In The City Of New York Procédés et compositions pour réguler l'efflux de cholestérol pour prévenir, traiter ou guérir une dégénérescence maculaire

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
KR20190060881A (ko) * 2010-04-23 2019-06-03 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 레베르 선천성 흑내장-1(lca1)의 치료를 위한 재조합 아데노-관련된 바이러스-구아닐레이트 사이클라제 조성물 및 방법
WO2012167109A2 (fr) * 2011-06-03 2012-12-06 Massachusetts Eye & Ear Infirmary Thérapie génique par rpgrip1 pour l'amaurose congénitale de leber
EP2872183B1 (fr) * 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Thérapie génique induite par vaa s'appliquant à la dégénérescence rétinienne liée à l'x de rpgr
US10982228B2 (en) * 2014-05-02 2021-04-20 Genzyme Corporation AAV vectors for retinal and CNS gene therapy
GB201412011D0 (en) 2014-07-04 2014-08-20 Ucl Business Plc Treatments
CN107206105A (zh) * 2014-07-24 2017-09-26 麻省眼耳科医院 色素性视网膜炎的rpgr基因疗法
JP6935049B2 (ja) * 2015-03-11 2021-09-15 アメリカ合衆国 Ｘ連鎖性網膜色素変性症の治療のためのｒｐ２及びｒｐｇｒベクター
EP3289080B1 (fr) * 2015-04-30 2021-08-25 The Trustees of Columbia University in the City of New York Thérapie génique pour maladies autosomiques dominantes
RU2764920C2 (ru) 2016-07-08 2022-01-24 Зе Трастис Оф Зе Юниверсити Оф Пенсильвания Способы и композиции для лечения нарушений и заболеваний, связанных с rdh12

Also Published As

Publication number Publication date
JP2023133434A (ja) 2023-09-22
IL274609A (en) 2020-06-30
MX2020005008A (es) 2020-11-06
CA3082586A1 (fr) 2019-05-23
IL308645A (en) 2024-01-01
EA202091194A1 (ru) 2020-08-14
BR112020009828A2 (pt) 2020-11-17
EP4364803A2 (fr) 2024-05-08
JP2021502978A (ja) 2021-02-04
PH12020551319A1 (en) 2021-09-01
US20230190884A1 (en) 2023-06-22
EP3710590A1 (fr) 2020-09-23
IL274609B1 (en) 2024-01-01
WO2019099696A1 (fr) 2019-05-23
SG11202004527YA (en) 2020-06-29
EP3710590A4 (fr) 2021-06-23
KR20200088385A (ko) 2020-07-22
IL274609B2 (en) 2024-05-01
CN117752822A (zh) 2024-03-26
CN111886340A (zh) 2020-11-03
AU2018367606A1 (en) 2020-06-25
US20190142909A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
MA49631A (fr) Méthodes de traitement de la fibrose kystique
MA54105A (fr) Méthodes de traitement de la fibrose kystique
ZA202006746B (en) Methods of treatment
CL2016002713A1 (es) Vectores de aav para la terapia génica de la retina y el snc
IL259877A (en) Adeno-type viral vectors used to treat spinal muscular atrophy
ZA201708039B (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
IL265528A (en) aav therapy for Huntington's disease
KR102502091B9 (ko) β-사르코글리칸 및 마이크로RNA-29의 아데노-관련 바이러스 벡터 전달 및 근이영양증의 처리
MA54227A (fr) Méthodes de traitement de la fibrose kystique
DK3393579T3 (da) Øjenbehandlingssystem
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
EP3543393A4 (fr) Appareil de traitement de vêtements
MA53329A (fr) Méthodes de traitement de l'épilepsie
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
MA40687A (fr) Méthodes et compositions de traitement de malformation vasculaire
TWI800561B (zh) 毛髮處理方法
SG11201710686PA (en) Hair treatment agent
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
MA50914A (fr) Vecteurs viraux comprenant des séquences codantes de rdh12 et méthodes de traitement de dystrophies rétiniennes
MA48625A (fr) Composés et méthodes de traitement de la douleur viscérale
GB201707207D0 (en) Treatment of type 1 diabetes
EP3296455A4 (fr) Appareil de traitement de vêtements
MA50749A (fr) Méthodes de traitement du syndrome d'alport
HK1252975A1 (zh) 布料及紡織品的處理方法